Document Detail


Estramustine phosphate--hormone, chemotherapeutic agent, or both?
MedLine Citation:
PMID:  6539998     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Estramustine phosphate, a combination steroid and alkylating agent, has been used for treatment of cancer of the prostate since 1969. We treated 32 patients with Stages C and D prostate cancer with this compound. Using the National Prostatic Cancer Project criteria of response, no patient achieved complete or partial objective response. Sixty-two per cent of the patients without prior hormonal manipulation and 12 per cent of those who were progressing following hormonal therapy met the criteria for a stable response. Both Stage C patients, 50 per cent of D1 and 28 per cent of D2 patients achieved disease stabilization for a mean duration of 14.8 months. There was no correlation between tumor grade and response to treatment. Fifty per cent of the patients whose elevated acid phosphatase declined remain stable, whereas 80 per cent in whom the acid phosphatase did not decline have progressed. Estramustine is effective in patients without prior hormonal manipulation. In those refractory to hormones, the prognosis is poor yet data exist to support the superiority of estramustine phosphate over conventional therapy.
Authors:
Y Walzer; J Oswalt; M S Soloway
Related Documents :
3120758 - Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer.
3945888 - Hepatic resection for metastases of the colon and rectum.
3708278 - Incidence of locally metastatic ('recurrent') cutaneous malignant melanoma following co...
543448 - Prognostic factors in pyriform sinus carcinoma.
23987158 - Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific ou...
1312908 - Treatment of inoperable hepatocellular carcinoma by intra-arterial lipiodol and 4'-epid...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Urology     Volume:  24     ISSN:  0090-4295     ISO Abbreviation:  Urology     Publication Date:  1984 Jul 
Date Detail:
Created Date:  1984-08-03     Completed Date:  1984-08-03     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  53-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Carcinoma / drug therapy*
Estramustine / therapeutic use*
Hormones
Humans
Male
Middle Aged
Nitrogen Mustard Compounds / therapeutic use*
Prostatic Neoplasms / drug therapy*
Grant Support
ID/Acronym/Agency:
CA20618/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Hormones; 0/Nitrogen Mustard Compounds; 2998-57-4/Estramustine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current status of adjuvant chemotherapy after radical cystectomy for deeply invasive bladder cancer.
Next Document:  Intravesical CDDP therapy compared with combined CDDP and external radiation in noninvasive bladder ...